[Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?]
/in Hyperthermia, International Publications, Pancreatic Cancer /von 2002-08-02 / Dtsch. Med. Wochenschr. 2002 Aug;127(31-32):1660The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2002-01-01 / Int J Gastrointest Cancer 2002;32(1):1-6Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines
/in International Publications, Pancreatic Cancer /von 2001-09-01 / Cancer Res. 2001 Sep;61(17):6445-50Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived from pancreatic and colorectal cancer patients
/in International Publications, Pancreatic Cancer /von 2000-08-01 / Int J Colorectal Dis 2000 Aug;15(4):197-205Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9 protein
/in International Publications, Pancreatic Cancer /von 2000-07-01 / J. Immunother. 2000 Jul-Aug;23(4):464-72A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
/in Breast Cancer, Colorectal Cancer, Dendritic Cells, International Publications, Ovarian Cancer, Pancreatic Cancer /von 1999-06-01 / Clin. Cancer Res. 1999 Jun;5(6):1331-8
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives